The International Agency for Research on Cancer (IARC) has classified caprolactam as Group 4, which means it is "probably not carcinogenic to humans." This classification indicates that there is inadequate evidence to consider caprolactam as a cancer-causing agent in humans and limited evidence of carcinogenicity in experimental animals.
